Tag Archive for: Collaboration

Fibrocor Therapeutics enters into research and development collaboration with McQuade Center for Strategic Research and Development to advance Alport Syndrome program

/in

Agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies through Phase 1b Deal is a major step forward for Fibrocor’s plans to develop FIB918, its monoclonal antibody for Alport Syndrome, a rare disease with very limited treatment options Fibrocor and MSRD intend […]

Read more

Collaboration between BRAIN Biotech and AMSilk: Protein engineering successfully improves structural proteins for performance materials

/in

First patent application registered BRAIN Biotech relies on protein engineering expertise and bioinformatics for rational protein design Zwingenberg / Neuried (Germany), March 5, 2024 – BRAIN Biotech AG, leading provider of solutions for the biologization of industry, and AMSilk GmbH, a global leader in advanced materials made from spider silk-based proteins, announce the successful completion […]

Read more

DelSiTech and Tolmar Announce Global License and Development Agreement

/in

Tolmar secures global license to DelSiTech’s Silica Matrix technology to develop and commercialize two undisclosed drug targets DelSiTech and Tolmar to expand development of additional drug products across a range of therapeutic areas DelSiTech is eligible to receive upfront payments, development and commercial milestone payments, and royalties on licensed products Turku, Finland and Dublin, Ireland […]

Read more

Futura Medical extends collaboration with Cooper Consumer Health

/in

Futura Medical plc (AIM: FUM) (“Futura” or the “Company”), the pharmaceutical company developing innovative sexual health products, today announces that it has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health (“Cooper”), a leading European independent self-care organisation, for the rights to commercialise Eroxon®, the Company’s topical, gel-based Erectile Dysfunction (“ED”) treatment, throughout the European […]

Read more

Poolbeg Pharma Partners with a Nasdaq-Listed Biopharma Company on its Oral Delivery Platform

/in

Strategic collaboration focussed on the development of an optimised drug for a metabolic condition using Poolbeg’s licensed oral delivery technology Collaboration may expand to a full licensing agreement 17 October 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces that it has signed a […]

Read more